104 related articles for article (PubMed ID: 12057049)
1. Mode of progression in smoldering multiple myeloma: a study of 406 patients.
Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV
Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628
[TBL] [Abstract][Full Text] [Related]
2. How I treat smoldering multiple myeloma.
Ghobrial IM; Landgren O
Blood; 2014 Nov; 124(23):3380-8. PubMed ID: 25298034
[TBL] [Abstract][Full Text] [Related]
3. Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients.
Rajkumar S; Abdallah N; Lakshman A; Kumar S; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz M; Lacy M; Hayman S; Buadi F; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel PL
Res Sq; 2023 Oct; ():. PubMed ID: 37961238
[TBL] [Abstract][Full Text] [Related]
4. Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.
Fakhri B; Fiala MA; Tuchman SA; Wildes TM
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):219-224. PubMed ID: 29429818
[TBL] [Abstract][Full Text] [Related]
5. Treatment and disease-related complications in multiple myeloma: Implications for survivorship.
Chakraborty R; Majhail NS
Am J Hematol; 2020 Jun; 95(6):672-690. PubMed ID: 32086970
[TBL] [Abstract][Full Text] [Related]
6. Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets.
Fiala MA; Dukeman J; Tuchman SA; Keller M; Vij R; Wildes TM
JCO Clin Cancer Inform; 2017; 1():. PubMed ID: 30547156
[TBL] [Abstract][Full Text] [Related]
7. Multiple Myeloma.
Vrtis MC
Home Healthc Now; 2024 May-Jun 01; 42(3):140-149. PubMed ID: 38709580
[TBL] [Abstract][Full Text] [Related]
8. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Ghobrial IM; Gormley N; Kumar SK; Mateos MV; Bergsagel PL; Chesi M; Dhodapkar MV; Dispenzieri A; Fonseca R; Getz G; Kastritis E; Kristinsson SY; Martinez-Climent JA; Manier S; Marinac CR; Maura F; Morgan GJ; Davies FE; Nadeem O; Nuvolone M; Paiva B; O'Donnell E; Prosper F; Shah UA; Sklavenitis-Pistofidis R; Sperling AS; Vassiliou GS; Munshi NC; Castle PE; Anderson KC; San Miguel JF
Blood Cancer Discov; 2024 May; 5(3):146-152. PubMed ID: 38441243
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Kawano Y; Fujiwara S; Wada N; Izaki M; Yuki H; Okuno Y; Iyama K; Yamasaki H; Sakai A; Mitsuya H; Hata H
Int J Oncol; 2012 Sep; 41(3):876-84. PubMed ID: 22766978
[TBL] [Abstract][Full Text] [Related]
10. Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma.
Nelson M; Brown RD; Gibson J; Joshua DE
Br J Haematol; 1992 Jun; 81(2):223-30. PubMed ID: 1643019
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.
Landgren O
Hematology Am Soc Hematol Educ Program; 2010; 2010():295-302. PubMed ID: 21239809
[TBL] [Abstract][Full Text] [Related]
12. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.
Waxman AJ; Kuehl M; Balakumaran A; Weiss B; Landgren O
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):248-57. PubMed ID: 20709660
[TBL] [Abstract][Full Text] [Related]
13. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma: diagnosis and treatment.
Nau KC; Lewis WD
Am Fam Physician; 2008 Oct; 78(7):853-9. PubMed ID: 18841734
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
17. Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
Fawole A; Abonour R; Stender M; Shatavi S; Gaikazian S; Anderson J; Jaiyesimi I
Leuk Lymphoma; 2015 Jan; 56(1):34-41. PubMed ID: 24564573
[TBL] [Abstract][Full Text] [Related]
18. Smoldering, asymptomatic stage 1, and indolent myeloma.
Greipp PR
Curr Treat Options Oncol; 2000 Jun; 1(2):119-26. PubMed ID: 12057049
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
